DBZ (Dibenzazepine)

Catalog No.S2711 Batch:S271103

Print

Technical Data

Formula

C26H23F2N3O3
Molecular Weight 463.48 CAS No. 209984-56-5
Solubility (25°C)* In vitro DMSO 93 mg/mL (200.65 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
0.5% hydroxyethyl cellulose
6.0mg/ml Taking the 1 mL working solution as an example, add 6 mg of this product to 1 ml of 0.5% hydroxyethyl cellulose clear solution, and mix evenly to form a uniform suspension. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.75mg/ml Taking the 1 mL working solution as an example, add 50 μL of 15 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
1.1mg/ml Taking the 1 mL working solution as an example, add 50 μL of 22 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description DBZ (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.
Targets
γ secretase [1]
(Cell-free assay)		 Notch [1]
(Cell-free assay)
2.6 nM 2.9 nM
In vitro YO-01027 interacts directly with theγ-secretase complex and targets the N-terminal Presenilin fragment. Increasing concentrations of YO-01027 administered to APPL- or Notch-expressing cells leads to the progressive accumulation of APPL CTF fragments and a decrease in NICD production in a strictly dose-dependent manner. [1] 10 μM of YO-01027 reduces breast cancer stem cells (BCSC) number and activity. [2] A recent research indicates YO-01027 impairs mucin protein MUC16 biosynthesis in a concentration-dependent manner in undifferentiated cells at both preconfluent and confluent stages through Notch inhibition, but not in postmitotic stratified cells. [3]
In vivo YO-01027, which is delivered 1 mg/mL by i.p. injection on the day of cell injection and every subsequent 3 days, YO-01027 significantly, decreases MCF7 but not MDA-MB-231 tumors and increases latency compared with control mice (18-28 days). YO-01027-treated MCF7 tumors that did form had significantly reduced tumor volumes. [2] Treatment of YO-01027 into C57BL/6 mice inhibits epithelial cell proliferation and induces goblet cell differentiation in intestinal adenomas in a dose-dependent manner. [4]

Protocol (from reference)

Kinase Assay:

[1]
  • Pharmacological Inhibition of γ-secretase Activity

    For YO-01027, pilot experiments are performed with different drug concentrations ranging from 0.1 nM to 250 nM to determine the effective linear range and maximal inhibition dose for YO-01027. YO-01027 is added at the required concentrations to the S2 cell medium upon induction of Notch or APPL expression, 6 hours before protein harvesting. For each sample, YO-01027 is also included at the corresponding concentration in the lysis buffer for protein extraction and immunoblot analysis.
Cell Assay:

[2]
  • Cell lines

    BCSC

  • Concentrations

    10 μM

  • Incubation Time

    3 days

  • Method

    Cells are resuspended at ≤1 × 106 in 100 μL sorting buffer (PBS containing 0.5% bovine serum albumin, 2 mM EDTA) and incubated with preconjugated primary antibodies BEREP4-FITC (1:10), CD44-APC (1:20), and CD24-PE (1:10) for 10 minutes at 4 °C. The cells are washed in PBS and centrifuged at 800 × g for 2 minutes. For analysis, cells are resuspended in 500 μL of sorting buffer and fluorescence is measured using FACSCalibur and analyzed using WinMIDI 2.8. For sorting, cells are resuspended in 1× HBSS after incubation with the primary antibodies. Cells are sorted, with HBSS as sheath fluid, at 16 p.s.i. using FACSAria. The CD24low cell population gated by FACS is the lowest quintile of CD24-positive cells plus all the CD24-negative cells.
Animal Study:

[4]
  • Animal Models

    C57BL/6 mice

  • Dosages

    0, 3, 10, 30 μmol/kg

  • Administration

    Injected daily intraperitoneally

Customer Product Validation

Data from [Data independently produced by Journal of Pharmaceutical Investigation, 2014, 10.1007/s40005-014-0151-2]

Data from [Data independently produced by , , Cancer Res, 2016, 76(6):1641-52]

Data from [Data independently produced by , , Stem Cells, 2017, 35(4):1028-1039]

Data from [Data independently produced by , , Am J Pathol, 2016, 186(11):2945-2956]

Selleck's DBZ (Dibenzazepine) has been cited by 40 publications

A noncoding variant confers pancreatic differentiation defect and contributes to diabetes susceptibility by recruiting RXRA [ Nat Commun, 2024, 15(1):9771] PubMed: 39532884
Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME [ J Exp Clin Cancer Res, 2024, 43(1):295] PubMed: 39491031
GPA33 expression in colorectal cancer can be induced by WNT inhibition and targeted by cellular therapy [ Oncogene, 2024, ] PubMed: 39472498
Patient-Induced Pluripotent Stem Cell-Derived Hepatostellate Organoids Establish a Basis for Liver Pathologies in Telomeropathies [ Cell Mol Gastroenterol Hepatol, 2023, 16(3):451-472] PubMed: 37302654
HDAC6 and ERK/ADAM17 Regulate VEGF-Induced NOTCH Signaling in Lung Endothelial Cells [ Cells, 2023, 12(18)2231] PubMed: 37759454
HDAC6 and ERK/ADAM17 Regulate VEGF-Induced NOTCH Signaling in Lung Endothelial Cells [ Cells, 2023, 12(18)2231] PubMed: 37759454
Incongruence between transcriptional and vascular pathophysiological cell states [ Nat Cardiovasc Res, 2023, 2:2023530-549] PubMed: 37745941
Incongruence between transcriptional and vascular pathophysiological cell states [ Nat Cardiovasc Res, 2023, 2:2023530-549] PubMed: 37745941
Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T cell killing [ Clin Cancer Res, 2022, CCR-22-1128] PubMed: 35920742
Notch signaling functions in noncanonical juxtacrine manner in platelets to amplify thrombogenicity [ Elife, 2022, 11e79590] PubMed: 36190110

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.